IYH iShares U.S. Healthcare ETF
Company Analysis
Latest News
Trump Nominates Dr. Heidi Overton for FDA, Signaling Vaccine Policy Shift
President Donald Trump nominated Dr. Heidi Overton to lead the Food and Drug Administration. Dr. Overton currently serves as a White House health policy aide...
Moderna, Merck shares surge on successful Phase 3 cancer vaccine trial
Merck and Moderna announced that their individualized neoantigen therapy, intismeran, met its primary endpoint in a Phase 3 melanoma trial. The combination of...
🟢 Health ETF (IYH) is trading 3.29% up today on melanoma-vaccine optimism
IYH is trading 3.29% up today as healthcare benefits from investor rotation away from technology amid elevated Treasury yields, geopolitical uncertainty, and...
BioMarin buys Alesta for $275M, targeting first oral rare bone drug
BioMarin Pharmaceutical signed a definitive agreement to acquire clinical-stage biotech Alesta Therapeutics. The deal centers on ALE1, an oral small molecule...
Bristol-Myers Squibb Wins FDA Approval for Iberdomide, Using Landmark Cancer Endpoint
The FDA approved Bristol-Myers Squibb’s iberdomide combination therapy for adults with relapsed or refractory multiple myeloma. This regimen combines...
UMCG backs low-cost digoxin, cutting heart failure hospitalizations by 25%
UMCG cardiologists found low-dose digoxin reduces heart failure hospitalizations by approximately 25%. Nature Medicine and the Journal of the American Medical...
Replimune Gains FDA Approval for TUDRIQEV, Transitioning to Commercial Stage
The FDA granted Replimune Group Inc. accelerated approval for its oncolytic immunotherapy, TUDRIQEV. The drug treats patients with advanced cutaneous melanoma...
Lantheus Wins FDA Approval for Tauklarify to Detect Alzheimer’s Protein
The U.S. Food and Drug Administration (FDA) approved Tauklarify (florquinitau F 18) for use in positron emission tomography (PET) scans. Lantheus Holdings...
Definium Therapeutics Hits Phase III Goal for LSD-Derived Anxiety Drug
Definium Therapeutics announced its LSD-derived oral drug, DT120, met the primary endpoint in the Phase III VOYAGE trial for Generalized Anxiety Disorder...
Eli Lilly sues six firms for selling unapproved obesity drug, retatrutide
Eli Lilly filed six lawsuits against U.S. medical spas and online sellers for marketing unapproved versions of retatrutide. The legal action targets a growing...
Cardinal Health jumps, driven by profit beat and $5 billion buyback
Cardinal Health (NYSE: CAH) reported fourth-quarter fiscal 2026 adjusted earnings of $2.91 per share. This result surpassed the Wall Street consensus estimate...
Bristol Myers Squibb invests $2.3B in Texas to accelerate drug production
Bristol Myers Squibb (BMS) will invest $2.3 billion to build a new manufacturing campus in Houston, Texas. The multi-modal facility will produce both small...
AstraZeneca eyes Bristol Myers merger, creating $400B oncology powerhouse
AstraZeneca is discussing a merger with U.S. rival Bristol Myers Squibb. The potential deal would value the combined pharmaceutical giant at nearly $400...
AstraZeneca eyes $400B Bristol Myers Squibb merger, targeting oncology dominance
Britain's AstraZeneca is reportedly discussing a merger with U.S. rival Bristol Myers Squibb. The potential deal values the combined company at nearly $400...
AstraZeneca and Bristol Myers Squibb in Talks for Potential $400B Mega-Merger
Britain's AstraZeneca is reportedly in discussions to merge with U.S. rival Bristol Myers Squibb in a deal that would create a pharmaceutical giant valued at...
Novartis Pluvicto Wins FDA Approval for Earlier Use, Doubling Patient Pool
The U.S. Food and Drug Administration (FDA) expanded the approval for Novartis’s targeted radioligand therapy, Pluvicto. The FDA now authorizes the drug for...
J&J secures $2.58B option for Sail Biomedicines, targeting in-body cell therapy
Johnson & Johnson secured an option to acquire Sail Biomedicines for up to $2.58 billion. This investment targets Sail’s novel in vivo chimeric antigen...
Argenx buys Forte Biosciences for $2.2B, targeting major autoimmune breakthrough
Argenx agreed to acquire Forte Biosciences in an all-cash transaction valued at $2.2 billion. The offer of $77 per share represents a significant premium for...
Argenx Buys Forte Biosciences for $2.2B, Expanding Autoimmune Pipeline
Argenx agreed to acquire Forte Biosciences in an all-cash transaction valued at approximately $2.2 billion. The offer price of $77 per share represents a 40.5%...
AstraZeneca Beats Q2 Profit Estimates, Boosts Dividend on Oncology Strength
AstraZeneca exceeded second-quarter 2026 profit expectations and reaffirmed its annual guidance. Core earnings reached $2.63 per share, surpassing the $2.48...